Exploring EGFR, Nectin-4, and TROP-2 as Therapeutic Targets for Bladder Cancer Photoimmunotherapy
Our findings suggest that PIT targeting EGFR, Nectin-4, or TROP-2 merits further preclinical development as a targeted therapeutic approach for NMIBC, including potential combinatorial or personalized strategies.
Authors
- Christian Gratzke (ORCID: https://orcid.org/0000-0003-4070-0952)
- Philipp Wolf (ORCID: https://orcid.org/0000-0001-6779-4325)
- Susanne Schultze-Seemann
- Daniel Bodo Werz (ORCID: https://orcid.org/0000-0002-3973-2212)
- Isis Wolf (ORCID: https://orcid.org/0000-0002-6462-9778)
- Arkadiusz Miernik (ORCID: https://orcid.org/0000-0001-5894-9647)
- J. Storz
- Nora Giess
- Céline Roider
Institutions
- University of Freiburg (DE)
- University Medical Center Freiburg (DE)
Publication Details
- Journal
- Molecules
- Published
- 2025-12-17
- DOI
- https://doi.org/10.3390/molecules30244802
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft
- Albert-Ludwigs-Universität Freiburg
- Technische Universität Braunschweig